Miles Carroll joined Public Health England (formerly known as the Health Protection Agency)) as Deputy Director, Head of Research at Porton Down in September 2008. In his current role he has strategic and operational responsibilities to ensure that the Department is at the forefront of translational research in the areas of high containment microbiology, infectious disease vaccines, therapeutics, diagnostics and decontamination.
Miles gained his PhD from the Medical Faculty at the University of Manchester which enabled him to obtain an International Fogarty Fellowship and continue his studies on recombinant poxviruses at the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.
On his return to the UK, Miles Joined Oxford Biomedica as Vice President of Immunotherapy. At OBM Miles invented the cancer vaccine, TroVax and led the pre-clinical and Phase II development programme. In 2004, Miles joined the small molecule biotech company MNL Pharma as Chief Scientific Officer before working with UK universities and government research institutes in 2006 to raise external funding to commercialise their technologies.
Miles has authored approx 50 publications primarily in the field of recombinant vaccines, and has 10 granted patents. He has acted as an advisor to several biotech companies, appeared as an expert witness in both European and US patent cases and advised US Government on bio-defense issues. In 2011, Miles was awarded the title of Honorary Professor in Vaccinology at the University of Southampton.